Inpharmatica

Inpharmatica specializes in drug discovery services, utilizing advanced predictive informatics and proprietary technologies to streamline medicinal chemistry and ADME processes for pharmaceutical and biotechnology industries. Inpharmatica, founded in 1998 and headquartered in London, UK, focuses on enhancing drug discovery through innovative informatics solutions. The company has undergone no significant pivots and does not have known subsidiaries. The founder's history is not detailed.

Inpharmatica recently completed a Series C funding round, raising GBP 13. 90 mn, with REV Venture Partners as the lead investor, alongside investors such as 3i, Abingworth, Advent Venture Partners, and Gimv. The total amount raised to date is GBP 13. 90 mn.

Inpharmatica offers a suite of advanced services that enhance drug discovery through predictive informatics in medicinal chemistry and ADME (Absorption, Distribution, Metabolism, and Excretion). Central to their offerings are proprietary technologies such as Chemogenomics, which leverages extensive drug discovery databases to streamline the identification of viable drug candidates. Additionally, their Silico services combine optimization techniques with in silico tools, providing clients with expert assessments that aid in the early selection of compounds with desirable properties. These services are tailored for collaborations, project-based engagements, or licensing opportunities, catering primarily to global pharmaceutical and biotechnology companies, including industry leaders like Pfizer, GSK, and Sanofi-Aventis.

Inpharmatica’s products and services are utilized across major markets, including North America, Europe, and parts of Asia, ensuring a wide-reaching impact on drug development processes. Inpharmatica generated revenue of GBP 25,463,244 in 2023, with an EBITDA of GBP 682,677. The company generates revenue through a combination of service contracts, research collaborations, and licensing agreements for its proprietary technologies. Transactions primarily occur on a B2B basis with pharmaceutical and biotechnology companies, where clients engage in tailored research projects or subscribe to specific services, including access to Inpharmatica’s unique databases like StARLITe™, DrugStore™, and GPCR SARfari™.

The structure of these arrangements often involves upfront payments combined with milestone payments upon reaching certain project objectives, while licensing agreements for their in silico optimization technology are established for on-site installations, providing additional revenue streams. Inpharmatica plans to expand its product offerings by launching new services designed to meet the evolving needs of the pharmaceutical industry. The company aims to penetrate new markets in Asia by the end of 2024, leveraging its recently raised funds from the Series C round to support this initiative. Additionally, the funding will facilitate the development of new technologies and enhance its existing product line, aligning with the company's strategic growth objectives.